Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
ProceedingsPOSTER TOUR PRESENTATIONS
Open Access

A PRELIMINARY STUDY OF THE RELATIONSHIP BETWEEN PLASMA MICROBIAL CELL-FREE DNA AND DISEASE ACTIVITY IN PATIENTS WITH LUPUS

Shiv Kale, Paul Babb, Roberto Caricchio, Amanda Eudy, David Pisetsky, Jennifer Rogers and Sivan Bercovici
The Journal of Rheumatology May 2025, 52 (Suppl 1) 64; DOI: https://doi.org/10.3899/jrheum.2025-0390.PT001
Shiv Kale
1Karius, Biomarker Discovery, Redwood City, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Babb
1Karius, Biomarker Discovery, Redwood City, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roberto Caricchio
2UMass Chan Medical School, Worcester, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda Eudy
3Duke University School of Medicine, Durham, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Pisetsky
3Duke University School of Medicine, Durham, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Rogers
3Duke University School of Medicine, Durham, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sivan Bercovici
1Karius, Biomarker Discovery, Redwood City, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Previous
Loading

Abstract

PT001 / #268

Topic: AS04 - Biomarkers

POSTER TOUR 02: RECENT INSIGHTS ON THE PATHOGENESIS OF LUPUS NEPHRITIS

23-05-2025 10:00 AM - 10:40 AM

Background/Purpose Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by widespread tissue inflammation and damage in association with antinuclear antibody production. Emerging research suggests that disturbances in the microbiome (dysbiosis) can interact with the immune system to drive pathogenesis. Microbial cell-free DNA (mcfDNA) in plasma, analogous to human cell-free DNA, is thought to originate from microbial organisms undergoing cellular turnover. These microbial derived DNA fragments can transverse into the bloodstream and may be processed by circulating DNases. However, these degraded fragments may also be readily detected, identified, and quantified in plasma using advanced molecular and bioinformatics methodologies. The purpose of this pilot study was to explore a possible relationship between plasma mcfDNA and disease activity in patients with lupus.

Methods Plasma samples from patients with lupus were collected at 2 clinical centers. Patients were clustered into 3 groups: complete remission, remission with a positive anti-dsDNA titre, and active disease (SLEDAI greater > 6) with a positive anti-dsDNA titre. Specimens from a healthy cohort were derived from an independent collection center. Plasma was collected, processed, and stored in K2-EDTA tubes. Cell-free DNA was extracted from plasma via the Karius Discovery assay and sequenced at a depth of 400M paired-end reads per sample. A set of analytical filters was applied to control for contamination, separating biological signals from background. Differential abundance analysis, correlation analysis, and principal coordinate analysis were conducted to identify microbial signatures that discriminated between the healthy and lupus patient populations as well as the disease activity groupings. Identified features were incorporated into a gradient-boosted machine learning classifier to assess their predictive power.

Results Our study included 54 patients with SLE (median age 37.5 years, 46% had a history of lupus nephritis, 85% female) and 36 healthy controls (median age 45 years, 61% female). Our analysis indicated specific elevated microbial species, estimated in molecules per microliter (MPM), with concordant findings observed across both clinical centers. The mcfDNA that were identified were associated with the oral (Streptococcus, Prevotella, Porphyromonas, and Veillonella species); gastro-intestinal (Bacteroides, Alcaligenes, Streptomyces, and Campylobacter species); and skin (Staphylococcus, Corynebacterium, and Acintobacter species) microbiomes (Figure 1). Principal coordinate analysis and preliminary machine learning classifiers suggested a possible partition between the healthy individuals and those with lupus (Figure 2). The analysis also indicated that a subset of the microbial signatures may differentiate between disease activity groupings.

  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Conclusions Our pilot study provides preliminary data suggesting an increase in mcfDNA concentration from signature microbial species that can distinguish patients with SLE from controls and differentiate between disease subgroups. Further studies, including longitudinal analyses of larger and more diverse patient cohorts, will be needed to determine the utility of plasma mcfDNA as a biomarker for disease activity and delineate mechanisms by which increased mcfDNA may arise and contribute to pathogenesis.

  • Copyright © 2025 by the Journal of Rheumatology

This is an Open Access article, which permits use, distribution, and reproduction, without modification, provided the original article is correctly cited and is not used for commercial purposes.

Previous
Back to top

In this issue

The Journal of Rheumatology
Vol. 52, Issue Suppl 1
21 May 2025
  • Complete Issue (PDF)
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A PRELIMINARY STUDY OF THE RELATIONSHIP BETWEEN PLASMA MICROBIAL CELL-FREE DNA AND DISEASE ACTIVITY IN PATIENTS WITH LUPUS
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A PRELIMINARY STUDY OF THE RELATIONSHIP BETWEEN PLASMA MICROBIAL CELL-FREE DNA AND DISEASE ACTIVITY IN PATIENTS WITH LUPUS
Shiv Kale, Paul Babb, Roberto Caricchio, Amanda Eudy, David Pisetsky, Jennifer Rogers, Sivan Bercovici
The Journal of Rheumatology May 2025, 52 (Suppl 1) 64; DOI: 10.3899/jrheum.2025-0390.PT001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
A PRELIMINARY STUDY OF THE RELATIONSHIP BETWEEN PLASMA MICROBIAL CELL-FREE DNA AND DISEASE ACTIVITY IN PATIENTS WITH LUPUS
Shiv Kale, Paul Babb, Roberto Caricchio, Amanda Eudy, David Pisetsky, Jennifer Rogers, Sivan Bercovici
The Journal of Rheumatology May 2025, 52 (Suppl 1) 64; DOI: 10.3899/jrheum.2025-0390.PT001
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • XIST EXPRESSION IN MALES WITH SYSTEMIC LUPUS ERYTHEMATOSUS: BIMODAL DISTRIBUTION AND PARTIAL X-CHROMOSOME INACTIVATION
  • FEASIBILITY AND USABILITY OF A CLINICAL DECISION SUPPORT SYSTEM FOR TREAT-TO-TARGET IN SYSTEMIC LUPUS ERYTHEMATOSUS: THE T2T-SLE PILOT STUDY
  • IMPACT OF BELIMUMAB ON EFFICACY, SAFETY AND IMMUNE PHENOTYPES IN REFRACTORY AND ACTIVE LUPUS NEPHRITIS IN REAL-WORLD LOOPS REGISTRY
Show more POSTER TOUR PRESENTATIONS

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire